10-QPeriod: Q3 FY2007

QUEST DIAGNOSTICS INC Quarterly Report for Q3 Ended Sep 30, 2007

Filed October 25, 2007For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) reported its third-quarter and nine-month results for the period ending September 30, 2007. The company saw significant revenue growth, largely driven by strategic acquisitions, most notably AmeriPath for approximately $2 billion and HemoCue for approximately $450 million. This expansion has broadened its service offerings, particularly in anatomic pathology and point-of-care testing. Despite revenue growth, net income and earnings per share from continuing operations have seen a decline compared to the prior year. This is attributed to several factors including the integration costs associated with major acquisitions, a significant legal reserve established for government claims related to its discontinued NID subsidiary, and the ongoing impact of contract changes with major health plans like UnitedHealthcare (UNH). The company is actively managing costs and seeking operational efficiencies to mitigate these pressures.

Key Highlights

  • 1Quest Diagnostics completed two major acquisitions in 2007: AmeriPath for $2 billion and HemoCue for $450 million, significantly expanding its market presence and service portfolio.
  • 2Net revenues increased by 11.6% for the three months and 4.6% for the nine months ended September 30, 2007, driven by these acquisitions and organic growth in other segments.
  • 3Income from continuing operations decreased year-over-year, with diluted EPS at $0.77 for Q3 2007 compared to $0.82 in Q3 2006, and $2.05 for the nine months compared to $2.37.
  • 4A substantial reserve of $51 million was established for government claims related to the discontinued NID subsidiary, impacting discontinued operations negatively.
  • 5The company is actively pursuing cost reduction and efficiency initiatives, aiming to offset the impact of lost volume from payer contract changes and acquisition integration costs.
  • 6Operating income as a percentage of net revenue declined year-over-year, reflecting increased costs from acquisitions and operational adjustments.
  • 7Long-term debt significantly increased due to financing for acquisitions, rising from $1.24 billion at the end of 2006 to $3.47 billion by September 30, 2007.

Frequently Asked Questions

The primary drivers of revenue growth were significant strategic acquisitions, notably AmeriPath for approximately $2 billion and HemoCue for approximately $450 million. These acquisitions expanded the company's service offerings and market reach, particularly in anatomic pathology and point-of-care testing.

The decline in net income and EPS was influenced by several factors, including the substantial costs associated with integrating the newly acquired companies (AmeriPath and HemoCue), a significant $51 million reserve established for government claims related to the discontinued NID subsidiary, and the ongoing impact of losing preferred provider status with UnitedHealthcare (UNH), which affected testing volumes. The company is implementing cost-saving measures to mitigate these effects.

The $51 million reserve is related to government claims, including alleged violations of the False Claims Act and Food, Drug and Cosmetics Act, stemming from the operations of its former subsidiary, NID. While this reserve represents the minimum expected probable loss, the company notes that eventual losses could substantially exceed this amount and materially impact future results. This charge significantly impacted the 'Loss from discontinued operations' line item.

Quest Diagnostics' long-term debt has significantly increased, rising from approximately $1.24 billion at the end of 2006 to $3.47 billion by September 30, 2007. This increase is primarily due to new borrowings used to finance the major acquisitions of AmeriPath and HemoCue.